Nice coverage of the recent SMART-C collaborative meta-analysis in Circulation, led by Sid M. Patel Stephen Wiviott & TIMI Study Group

medicalrepublic.com.au/sglt2s-cut-car…

Next SMART-C presentation at ERA - European Renal Association: Effects of SGLT2i with & without GLP-1RA

Find out more at SMART-C.net

💊From SGLT2 inhibitors to mineralocorticoid receptor antagonists, we'll explore innovative treatments and new indications.
🎙️Join us in the 12th episode of our #ERAPodcast #APinchOfSalt 🧂with Katherine Tuttle.
🎧 Hit play now ⁣👉 bit.ly/3SdsxU0

Routinely collected primary care data from UK:

Combination SGLT2i and GLP1-RA associated with reduction in risk of major cardiovascular events and serious renal events compared to either alone

From Laurent Azoulay & colleagues in The BMJ

bmj.com/content/385/bm…

Dr Falk introducing Josie Briggs as the Blythe lecturer
UNC Kidney Center

Great read on the need for urgency to adopt green kidney care 👇

Did you know one HD session uses >500 L of water ? 💦🌲🌿☘️🌎

Great review of DUPLEX with first author Michelle Rheault and expert trialist Brendon Neuen

Great to see the rigorous study of sparsentan in FSGS, hopefully sets the stage for future efforts

podcasts.apple.com/us/podcast/fre…

A new approach to initiating guideline-directed medical therapy in patients with type 2 #diabetes & chronic #kidney disease has been proposed, with the benefits of prioritising absolute risk reduction & maximising cost effectiveness
Brendon Neuen Circulation
thelimbic.com/nephrology/how…

Super fun as always to join Freely Filtered: A NephJC Podcast - discussing all things FSGS, GFR slope / endpoint definitions, & lessons for next gen rare disease trials

Thanks Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Priya Yenebere Nayan Arora,MD Michelle Rheault for another fun episode

podcasts.apple.com/au/podcast/fre…

#nephjc

Effects of #GDMT across Kidney Function Spectrum

✅ #BB : consistent benefit to eGFR 30
✅ #ARNI : consistent benefit to eGFR 30
✅ #SGLT2i : consistent benefit to eGFR 20
❌ #SteroidalMRA : ↓ benefit & worse safety at lower eGFR

New strategies to block MR axis in HF & CKD needed!

Rich pipeline of alternative approaches to safely block MR axis being investigated in heart & kidney disease

🔥 K+ lowering therapies
🔥 Nonsteroidal MRAs
🔥 MR modulators
🔥 Aldosterone synthase inhibitors

👀 this rapidly changing space—upcoming HF RCTs to likely report '24 👇🏾

New in this episode of Freely Filtered: A NephJC Podcast, chapters!

nephjc.com/freelyfiltered…

Nick Mark MD Freely Filtered: A NephJC Podcast Chapters are supported in the podcast spec, it even allows you to change the episode with each chapter, we did this for chronic v total GFR slope which was relevant for this episode and it works across platform. See how chapters are displayed in Apple Podcasts on my iPhone.

I

Super fun as always to join Freely Filtered: A NephJC Podcast - discussing all things FSGS, GFR slope / endpoint definitions, & lessons for next gen rare disease trials

Thanks Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Priya Yenebere Nayan Arora,MD Michelle Rheault for another fun episode

podcasts.apple.com/au/podcast/fre…

#nephjc

Excited and proud to be part of the first regional World Health Summit to be held in Australia!

Looking forward to hearing some amazing talks and forging new connections to make serious headway in #healthequity in APAC and beyond.

AAMRI Public Health Australia UN Human Rights World Health Organization South-East Asia

#OnMyMind : Accelerated risk-based implementation of guideline-directed medical therapy (GDMT) for type 2 diabetes and chronic kidney disease (CKD) #AHAJournals ahajournals.org/doi/10.1161/CI…

Delighted to join the American Society of Nephrology Journals’ Editorial Board and look forward to working with Rajnish Mehrotra, Connie Rhee & all involved at these great journals to advance kidney science

An honor to present at the Global Trials Summit 2024 today with so many🌟in the field. The case for #ImplementationScience in #HF & broadly across #CKM could not be stronger - so many tools for patients & yet much more work to do. 🙏Mark Petrie Pardeep S Jhund Harriette Van Spall, MD MPH and team for the opportunity.

SGLT2 inhibitors reduce the risk of cardiovascular disease in patients with CKD. This study found SGLT2 inhibitors reduced risk of cardiovascular death, having the most pronounced effects on risk of deaths attributed to heart failure bit.ly/CJASN0470

David C Wheeler

ISOM 2024 Conference set for Sydney, Australia in October 2024, joint with SOMANZ

Proud to share our latest work in CJASN! SGLT2i reduce CV death in CKD by 20% overall, with most pronounced effects on deaths attributed to heart failure 🫀

A great team effort and thanks to all who contributed. 🤩

⛓️: journals.lww.com/cjasn/citation…